A big deal in biotech is going to line the pockets of some of Wall Street’s biggest firms. The biotech company Thermo Fisher Scientific has agreed to buy the drug-ingredients maker Patheon in a $7.2 billion deal. In a statement Monday, Thermo Fisher said it would acquire all outstanding Patheon shares for $35 apiece in cash, 35%
[Read More ...]
No comments:
Post a Comment